
This trial investigated immunosuppression post-lung transplantation, comparing tacrolimus (once daily) to ciclosporin (twice daily) regarding chronic lung allograft dysfunction (CLAD). In the modified intention-to-treat population, CLAD incidence at 36 months was significantly lower with tacrolimus (13%) compared to ciclosporin (39%). Tacrolimus demonstrated superior allograft survival in the per protocol CLAD population. While overall survival did not differ, these findings advocate tacrolimus as the preferred calcineurin inhibitor post-lung transplantation, potentially improving long-term outcomes.
Like
Save
Share